Pharmaceutical and Life Sciences Podcasting — Reaching the Practitioners Developing Tomorrow's Medicines
The pharmaceutical and life sciences industry is one of the most intellectually demanding, most heavily regulated, and most commercially significant sectors in the global economy. The scientists, physicians, regulatory specialists, clinical operations professionals, manufacturing experts, and commercial teams who bring new medicines and medical devices from discovery to patients are working in an environment where the stakes — in terms of both patient outcomes and commercial performance — are among the highest in any industry. The complexity of drug development, the rigor of regulatory requirements, and the scientific depth required to participate meaningfully in life sciences conversations make this one of the most challenging B2B podcast categories to produce well — and one of the most valuable when done with genuine expertise.
The life sciences podcast audience spans a range of professional roles: the medicinal chemist working on lead optimization in a drug discovery program, the clinical trial manager overseeing a Phase III study, the regulatory affairs specialist preparing an IND or NDA submission, the market access professional developing the payer strategy for a new therapy, and the commercial leader building the launch plan for a new medicine are all working on distinct phases of the drug development and commercialization process with distinct information needs and distinct professional communities.
Drug Discovery and the Science of Finding New Medicines
Drug discovery — the research process through which new potential medicines are identified and characterized sufficiently to advance into clinical development — is a scientifically intensive process with a high failure rate and a long timeline from initial discovery to clinical proof of concept. The scientists working in drug discovery — medicinal chemists, structural biologists, pharmacologists, computational chemists, and the increasingly important AI and machine learning scientists who are applying data-driven approaches to target identification and lead optimization — are working at the frontier of biological and chemical science with enormous consequences for future medicines.
A podcast that covers drug discovery with genuine scientific depth — featuring the research scientists who are developing novel approaches to target identification, the structural biologists who are using cryo-EM and other structural tools to enable structure-based drug design, the AI and machine learning researchers who are applying computational approaches to drug discovery, and the pharmaceutical company R&D leaders who are making strategic decisions about where to invest discovery resources — is serving a practitioner community that is working at the leading edge of biomedical science.
The commercial connections from drug discovery content are substantial: the contract research organizations that provide discovery services, the scientific software and informatics platforms that support discovery research, the laboratory equipment and reagent companies that supply drug discovery labs, and the specialized CROs and academic research institutions that provide capabilities in specific discovery domains are all relevant commercial contexts. The life sciences podcast that covers drug discovery with genuine scientific credibility is building relationships with practitioners who are making significant and ongoing purchasing decisions for research services and laboratory resources.
Clinical Development and Regulatory Affairs
Clinical development — the systematic evaluation of new medicines in human subjects, through the Phase I, II, and III trials required to demonstrate safety and efficacy for regulatory approval — is the most expensive and most uncertain phase of drug development. The investment required to conduct the clinical trials that support regulatory approval of a new medicine is enormous — often hundreds of millions to billions of dollars — and the failure rate is high even for medicines that have reached clinical development with genuine scientific rationale.
The clinical operations practitioners who design, conduct, and manage clinical trials are working in an environment of increasing complexity: decentralized clinical trial models that collect data from patients at home or at local healthcare providers rather than at central trial sites, the integration of electronic health records and wearable devices as clinical trial data sources, the global trial designs that enroll patients across dozens of countries with different regulatory requirements, and the increasing use of adaptive trial designs that allow protocol modifications based on emerging data are all changing how clinical trials are conducted.
Regulatory affairs — the interface between pharmaceutical companies and the regulatory agencies (FDA, EMA, and dozens of national regulatory authorities) that review and approve new medicines — is a domain with significant expertise requirements and significant commercial consequences. The regulatory strategy decisions that shape how a development program is structured, what clinical evidence is generated, and how that evidence is packaged and presented to regulators can make the difference between an efficient path to approval and years of additional development work required to address regulatory questions.
A life sciences podcast that covers clinical development and regulatory affairs with genuine technical and regulatory depth — featuring the clinical operations leaders who have managed complex global trials, the regulatory affairs professionals who have navigated successful FDA and EMA submissions, and the regulatory scientists who study the evidence standards that shape drug approval decisions — is serving a practitioner audience that is making consequential decisions where the cost of errors is measured in years of development time and billions of dollars of delayed or lost commercial opportunity.
Manufacturing and Supply Chain for Life Sciences
Pharmaceutical manufacturing is one of the most heavily regulated manufacturing environments in any industry: the Good Manufacturing Practice (GMP) requirements that govern pharmaceutical production, the validation requirements for manufacturing processes and equipment, and the quality systems that ensure product consistency and safety are all more demanding than manufacturing requirements in virtually any other sector. The pharmaceutical manufacturing professional — the process engineer who develops and validates manufacturing processes, the quality director who manages the quality systems required by GMP regulations, and the supply chain manager who ensures reliable supply of both materials and finished product — is working in an environment where manufacturing errors have direct patient safety consequences.
Biologics manufacturing — the production of complex protein-based medicines like monoclonal antibodies, gene therapies, and cell therapies — presents particularly significant technical challenges. Biologic manufacturing involves living cell culture systems that are inherently variable, purification processes that must remove process-related impurities while preserving the biological activity of the product, and quality control testing that must characterize complex molecules with many-dimensional attributes. The scientists and engineers who develop and scale biologic manufacturing processes are working at the frontier of biotechnology manufacturing with genuine technical complexity.
The pharmaceutical supply chain has received heightened attention since the COVID-19 pandemic exposed the vulnerabilities of global pharmaceutical supply chains that are dependent on active pharmaceutical ingredient manufacturing concentrated in a small number of countries. The reshoring and supply chain diversification strategies that pharmaceutical companies are pursuing in response to these vulnerabilities, the regulatory frameworks that encourage domestic manufacturing of critical medicines, and the technology investments that are improving pharmaceutical supply chain visibility and resilience are all topics with genuine practitioner depth.
Medical Affairs and Scientific Communication
Medical affairs — the function within pharmaceutical companies that serves as the scientific interface between the company and the medical community — has grown in importance as regulatory and compliance requirements have increasingly constrained the promotional activities of commercial teams. Medical science liaisons (MSLs), the field-based medical affairs professionals who engage in peer-to-peer scientific exchange with key opinion leaders and clinical experts, are increasingly important to the scientific communication strategy of pharmaceutical companies. The medical affairs professionals who design and execute medical education programs, develop evidence communication strategies, and manage the scientific information functions that respond to medical inquiries from healthcare providers are working in a domain that is both scientifically demanding and commercially consequential.
A life sciences podcast that covers medical affairs with genuine scientific and strategic depth — featuring the medical affairs executives who have built effective MSL teams, the scientific communication specialists who develop evidence communication strategies, and the medical education experts who design programs that genuinely advance physician knowledge — is serving a practitioner community that is working at the intersection of scientific rigor and commercial reality in ways that require both deep scientific expertise and sophisticated understanding of how companies can engage with the medical community within appropriate compliance boundaries.
Market Access and the Payer Landscape
The ability to bring a new medicine to market successfully is not solely determined by regulatory approval: the market access decisions that determine whether payers — government health programs, private insurers, pharmacy benefit managers — will cover the new therapy and at what price are increasingly critical determinants of commercial success. The market access professionals who develop payer strategy, negotiate coverage terms, and demonstrate the value of new medicines to health technology assessment bodies are working in a domain that has grown in importance as payers have become more rigorous in evaluating the clinical and economic evidence supporting new therapy coverage decisions.
Health technology assessment (HTA) — the systematic evaluation of the clinical and economic value of new medicines by bodies like NICE in the UK, HAS in France, and IQWiG in Germany — has become a major determinant of medicine access in many markets, and the skills required to navigate HTA processes are distinct from those required to navigate clinical regulatory submissions. The market access professional who can develop a compelling health economic model, present a coherent value story to payer decision-makers, and negotiate access agreements that balance company commercial objectives with payer cost management goals is working with a specialized combination of clinical, economic, and negotiation expertise.
The pharmaceutical podcast that covers market access and health economics with genuine depth — featuring the market access executives who have navigated successful payer negotiations for innovative medicines, the health economists who develop the models and evidence syntheses that support HTA submissions, and the policy researchers who study the effects of HTA decisions on medicine access and innovation incentives — is serving a practitioner community that is working on one of the most commercially consequential aspects of pharmaceutical commercialization.
Building the Life Sciences Podcast with Scientific Credibility
The life sciences podcast faces a distinctive credibility challenge: the scientific depth required to serve a practitioner audience of researchers, clinicians, and regulatory professionals is genuinely high, and the host or producer who lacks genuine scientific understanding will be quickly identified by a sophisticated audience whose professional credibility depends on accurate scientific information. Building a life sciences podcast that earns genuine practitioner trust requires either a host with genuine scientific credentials and understanding or a production process that involves deep collaboration with scientific advisors who can ensure accuracy and appropriate framing of complex scientific questions.
The conference infrastructure of the life sciences industry provides rich content production opportunities: the American Society of Clinical Oncology, the American Chemical Society, BIO, DIA, and dozens of therapeutic area-specific medical conferences create regular concentrations of the practitioners who are doing the most important work in life sciences. The life sciences podcast that treats these conferences as content production events — recording interviews with leading researchers, clinicians, and industry experts gathered in one place — is building a content calendar with the kind of practitioner depth that establishes genuine scientific credibility over time.
Oncology and Rare Disease — The Highest-Stakes Commercial Territories
Oncology has become the dominant therapeutic area in pharmaceutical R&D: the scientific understanding of cancer biology has advanced dramatically through the genomic revolution, and the resulting wave of targeted therapies, immunotherapies, and cell therapies has transformed outcomes for many cancers while creating an intensely competitive commercial landscape where dozens of therapies compete in specific cancer subtypes defined by molecular markers. The oncology practitioners — the oncologists who select therapies, the oncology nurses who administer them, the oncology pharmacists who manage the complex drug protocols, and the patient advocacy organizations that support cancer patients — are all part of an ecosystem with enormous commercial significance and profound human stakes.
Rare disease has become another major focus of pharmaceutical development, driven both by the scientific opportunity created by orphan drug designation and expedited regulatory pathways and by the commercial potential of therapies serving small patient populations with limited treatment alternatives who can command premium pricing. The rare disease practitioner — the medical geneticist who diagnoses rare genetic conditions, the metabolic specialist who manages complex rare metabolic diseases, and the patient advocacy organization that connects patients with clinical trials and new therapies — is working in a domain where individual therapy decisions have immediate and profound consequences for patients and families.
A life sciences podcast that covers oncology and rare disease with genuine scientific and clinical depth — featuring the oncologists who are navigating complex treatment decisions, the clinical trial investigators who are testing new approaches to cancer therapy, and the regulatory and market access specialists who are navigating the complex commercial pathways for rare disease therapies — is serving a commercially significant practitioner audience where the stakes of practitioner education are unusually high.
Health Economics and Outcomes Research
Health economics and outcomes research (HEOR) — the discipline that generates the evidence base for value assessments of healthcare interventions, including cost-effectiveness analyses, budget impact models, and real-world evidence studies — has become increasingly central to pharmaceutical market access and reimbursement decisions. The HEOR practitioners who develop the health economic models that support HTA submissions, design the real-world evidence studies that demonstrate therapy effectiveness in clinical practice, and translate complex economic evidence for payer audiences are working in a domain that sits at the intersection of clinical science, economics, and health policy.
The real-world evidence revolution — the use of electronic health record data, claims data, patient registries, and other real-world data sources to generate evidence about how medicines perform in clinical practice — is transforming both drug development and market access. Real-world evidence is increasingly being used to support regulatory applications for expanded indications, to demonstrate comparative effectiveness for payer audiences, and to inform post-market safety surveillance. The practitioners building real-world evidence programs — the epidemiologists who design real-world studies, the data scientists who analyze complex healthcare databases, and the regulatory specialists who navigate the evolving standards for real-world evidence in regulatory submissions — are working at one of the most active frontiers of pharmaceutical evidence generation.
Patient Centricity and the Evolving Role of Patient Input
The pharmaceutical industry's embrace of patient centricity — genuinely incorporating patient perspectives, preferences, and experiences into drug development and regulatory processes — has moved from aspirational language to operational practice over the past decade, driven by regulatory encouragement, patient advocacy pressure, and the growing recognition that medicines developed with genuine understanding of patient experience are more likely to meet patients' actual needs. The patient engagement specialists who design programs to incorporate patient input into clinical trial design, the regulatory affairs professionals who build patient-focused drug development frameworks into regulatory submissions, and the patient advocacy organization staff who work at the interface between the patient community and the pharmaceutical and regulatory ecosystem are all working in a domain that is both ethically important and practically consequential for the quality of medicines that reach patients.
A life sciences podcast that covers patient centricity with genuine commitment to the patient perspective — featuring the patient advocates who have influenced drug development programs, the researchers who study patient preferences and treatment burden, and the pharmaceutical executives who have built genuine patient engagement programs — is providing content that connects the commercial imperatives of drug development to the human stakes of medicine. This is the dimension of life sciences content that has the deepest resonance with audiences who came to the pharmaceutical industry because they care about improving human health, and that reminds the entire practitioner community why the work they do matters beyond the commercial performance metrics that dominate most pharmaceutical business discussions.
Pharmaceutical Commercial Excellence and Launch Planning
The commercial launch of a new medicine — the period from regulatory approval to achieving significant market penetration — is one of the highest-stakes commercial events in the pharmaceutical industry. The launch planning process begins years before approval, encompasses the medical affairs programs that build scientific understanding of the new therapy's value, the market access negotiations that determine coverage, the patient support programs that help patients access therapy, and the commercial execution that drives prescriber adoption. Getting launch right is commercially critical: the revenue trajectory established in the first 12 to 24 months following launch typically determines whether a medicine achieves its commercial potential or disappoints relative to development investment.
The commercial excellence function in pharmaceutical companies — the sales force effectiveness, marketing analytics, and commercial operations capabilities that support field execution — has evolved significantly as digital engagement has become central to how pharmaceutical companies interact with healthcare providers. The sales representative who can no longer rely on office visits alone, the medical science liaison who supplements field engagement with digital outreach, and the marketing team that must reach physicians across an ever-more-fragmented media landscape are all navigating a commercial environment that is fundamentally different from the blockbuster era of pharmaceutical marketing.
Building Life Sciences Podcast Credibility Over Time
The life sciences podcast that earns genuine scientific credibility takes time — there are no shortcuts to the reputation that develops from consistently producing content that the practitioner community finds technically accurate, scientifically rigorous, and professionally relevant. The most important early investment is in establishing relationships with respected scientific and clinical thought leaders who will participate as guests: the endorsement implicit in a respected researcher's or clinician's willingness to participate in the podcast is itself a credibility signal that opens doors to subsequent guests and helps audiences calibrate the show's scientific standards.
The long-term value of life sciences podcast investment reflects the long timeline of the pharmaceutical industry itself: drug development programs take 10 to 15 years from initial discovery to regulatory approval, and the commercial relationships between pharmaceutical companies and the service providers, technology companies, and research institutions that support drug development are similarly long-duration. The podcast that builds genuine scientific credibility and maintains it consistently over years is building an institutional presence in the life sciences ecosystem that compounds in audience trust, practitioner relationships, and commercial significance in ways that no short-term content investment can replicate.
Contract Research Organizations and the Outsourced Drug Development Model
The drug development process is increasingly executed through a partnership model between pharmaceutical companies and contract research organizations (CROs), contract manufacturing organizations (CMOs), and the growing ecosystem of specialized service providers who perform specific aspects of drug development on an outsourced basis. The CRO model — where pharmaceutical companies contract with specialized organizations to conduct preclinical studies, clinical trials, regulatory submissions, and other drug development activities — has grown to represent a significant fraction of all pharmaceutical development work.
The practitioners managing these outsourced relationships — the pharmaceutical company alliance managers who oversee CRO relationships, the CRO project managers who coordinate complex multi-site clinical trials, and the procurement and vendor management specialists who select and manage the service provider relationships that support drug development programs — are working in a domain with significant operational and financial complexity. CRO selection decisions involve trade-offs between cost, quality, therapeutic area expertise, geographic reach, and the capacity to execute at the pace that pharmaceutical development programs require.
A life sciences podcast that covers the CRO and outsourced development model with genuine operational depth — featuring the pharma alliance management professionals who have built effective CRO relationships, the CRO leaders who understand what distinguishes successful from unsuccessful outsourced development partnerships, and the clinical operations specialists who manage the operational complexity of large outsourced clinical trials — is serving a practitioner community that is making significant and consequential operational decisions every day.
Biologics and the Cell and Gene Therapy Revolution
The shift from small molecule drugs — the traditional chemical compounds that have dominated pharmaceutical development for most of the industry's history — to biologics and advanced therapies including cell therapies and gene therapies represents one of the most significant technological transitions in the history of medicine. Biologics — complex protein-based medicines produced through biological manufacturing processes — are already the dominant category in pharmaceutical revenue and R&D investment, and cell and gene therapies represent the frontier of a new generation of medicines that aim to treat or even cure diseases at their genetic and cellular roots.
Cell therapies — living cell-based medicines that include CAR-T therapies for blood cancers and the emerging generation of solid tumor and autoimmune cell therapies — present manufacturing challenges that are unlike those for any conventional medicine: the cells themselves are living biological systems that must be collected from patients, engineered, expanded in manufacturing, and reinfused — all within quality systems that ensure the safety and potency of what is, in effect, a living medicine. Gene therapies — which aim to correct disease-causing genetic defects by delivering functional copies of genes to patients' cells — face their own distinctive manufacturing and delivery challenges involving the viral vectors that carry therapeutic genes to their target cells.
The practitioners working in cell and gene therapy — the manufacturing scientists who develop the processes to produce these complex therapies at commercial scale, the clinical teams who administer them in highly specialized clinical settings, and the regulatory specialists who navigate the novel regulatory frameworks for these unprecedented medicine types — are working at the frontier of biomedical science with immense potential and genuine operational complexity. The life sciences podcast that covers cell and gene therapy with genuine scientific and manufacturing depth is building credibility in one of the most scientifically exciting and commercially significant areas of pharmaceutical development.
Global Regulatory Harmonization and International Drug Development
Drug development is increasingly a global enterprise: the clinical evidence required to support regulatory approval in major markets must often be generated across multiple countries, and the regulatory submissions that support approval must satisfy the requirements of regulatory authorities with different standards and different review processes. The International Council for Harmonisation (ICH) has worked for decades to align the technical requirements for pharmaceutical development across the major pharmaceutical markets — the US, EU, Japan, and increasingly China and other major markets — but significant differences in regulatory expectations persist.
The regulatory strategist who plans the global development program for a new medicine — determining which countries to include in clinical trials to generate the data that will support approval in each target market, how to sequence regulatory submissions across markets, and how to engage with regulatory agencies in key markets during development — is working with specialized expertise that has significant commercial consequences. Regulatory strategy decisions made early in drug development affect the design of clinical programs that will determine regulatory success years later, and the cost of getting these decisions wrong is measured in years of additional development time and billions of dollars of delayed or lost revenue.
A life sciences podcast that covers global regulatory affairs with genuine expertise across multiple jurisdictions — featuring the global regulatory affairs professionals who have navigated major regulatory submissions across multiple markets, the regulatory agency alumni who can provide insight into how regulators evaluate development programs, and the international pharmaceutical policy researchers who study how regulatory harmonization affects global drug development — is serving a practitioner community whose decisions have global implications for both pharmaceutical development efficiency and patient access to medicines around the world.
Pharmacovigilance and Post-Market Drug Safety
The drug development process does not end with regulatory approval: the pharmacovigilance systems that monitor drug safety after market approval are a regulatory requirement and a patient safety imperative that pharmaceutical companies maintain throughout the commercial life of their medicines. The pharmacovigilance practitioners — the drug safety scientists who evaluate adverse event reports, the signal detection specialists who identify emerging safety patterns in large safety databases, the regulatory affairs professionals who manage safety reporting obligations across multiple markets, and the risk management specialists who develop and implement the risk minimization programs that address identified safety concerns — are working in a domain where their effectiveness has direct consequences for patient safety.
The pharmacovigilance regulatory environment has grown more complex as the number of marketed medicines and the volume of safety data have grown: the automated adverse event reporting systems, the electronic submissions infrastructure, and the safety database platforms that manage large volumes of case safety reports are all part of the pharmacovigilance technology ecosystem that the life sciences podcast covering drug safety can address with genuine technical depth. The commercial market for pharmacovigilance technology and services is substantial, making this an area where the life sciences podcast builds commercially connected relationships alongside the patient safety content that gives pharmacovigilance its genuine importance.
Pharmaceutical Pricing and Reimbursement Policy
Pharmaceutical pricing has become one of the most politically contested topics in healthcare policy, with significant implications for pharmaceutical company commercial strategy, for patient access to medicines, and for the sustainability of healthcare systems that must allocate limited budgets across a growing range of effective but expensive therapies. The practitioners working on pharmaceutical pricing — the market access professionals who develop pricing strategies, the health economists who model the value that new medicines deliver relative to their costs, and the policy professionals who are designing the regulatory frameworks that govern pharmaceutical pricing — are working at the intersection of commercial strategy and healthcare policy in ways that have become increasingly consequential and increasingly public.
The Inflation Reduction Act's provisions for Medicare drug price negotiation, the reference pricing frameworks that many countries use to benchmark pharmaceutical prices against international comparators, and the outcomes-based contracting models that are emerging as alternatives to traditional fee-for-service drug purchasing are all reshaping the market access and pricing environment that pharmaceutical companies navigate. The pharmaceutical market access professional who understands these policy developments and their commercial implications is working with specialized expertise that the commercial leadership of pharmaceutical companies needs and that a genuinely expert pharmaceutical podcast can uniquely serve.
Personalized Medicine and Biomarker-Driven Development
Personalized medicine — the development of medicines for defined patient subpopulations identified by specific genetic, molecular, or clinical biomarkers — has transformed drug development across multiple therapeutic areas, particularly in oncology. The ability to identify the specific patient population most likely to benefit from a new therapy, and to design clinical trials that demonstrate benefit in that population, has made drug development both more scientifically precise and more commercially complex: the companion diagnostic that identifies the biomarker-defined population must be developed alongside the therapy, regulatory approval for both the therapy and the diagnostic must be coordinated, and the market access strategy for a precision medicine must address a smaller but often more clearly defined patient population.
The biomarker development and companion diagnostic dimension of personalized medicine development has created significant practitioner content needs: the scientists who develop and validate biomarker assays, the regulatory specialists who navigate the co-development and co-approval of therapy and diagnostic, and the market access professionals who develop the payer strategy for precision medicines are all working with specialized expertise that the life sciences podcast with genuine scientific depth can address.
The future of personalized medicine extends beyond the targeted therapies that currently define the category: the polygenic risk scores that identify individuals at elevated risk for complex diseases, the liquid biopsy technologies that detect cancer-associated DNA in blood, and the multi-omics platforms that integrate genomic, proteomic, and metabolomic data to characterize individual health status are all potential foundations for the next generation of personalized prevention and treatment approaches. The life sciences podcast that covers these developments with genuine scientific sophistication is tracking one of the most important frontiers of biomedical science and building relationships with the practitioners who are doing the most intellectually exciting work in medicine.
The Life Sciences Podcast as Community Infrastructure
The life sciences practitioner community is global, specialized, and distributed across academic research institutions, pharmaceutical and biotech companies, hospitals and clinical research sites, regulatory agencies, and the service provider ecosystem that supports drug development. Building community across this distributed ecosystem has historically relied on large conferences like AACR, ASCO, and ASH in oncology, or on the therapeutic area-specific societies that serve other disease areas. The podcast that covers its therapeutic area or functional domain consistently and with genuine expertise becomes part of this community infrastructure — a resource that practitioners recommend to colleagues, that early career scientists use to develop their understanding of the field, and that serves as a touchstone for the conversations that shape how a professional community thinks about the most important questions in its domain.
This community infrastructure role is the most ambitious and the most valuable version of the life sciences podcast — and achieving it requires the consistent investment in scientific quality, guest relationships, and editorial judgment that distinguishes the show that merely covers life sciences news from the show that genuinely serves the life sciences practitioner community over the long arc of scientific progress.
The life sciences industry's most important conversations — the ones about whether a development program's scientific rationale is strong enough to justify continued investment, whether a regulatory strategy will support efficient approval, whether a market access approach will achieve meaningful patient access — happen in conference rooms and laboratory corridors where outside observation is rarely possible. The podcast that earns the trust of the practitioners having these conversations — that creates the conditions where they're willing to share their thinking, their frameworks, and the hard-won lessons of their experience — is providing a window into the intellectual life of drug development that is genuinely rare and genuinely valuable. Building that trust, maintaining it over time, and consistently earning the right to conversations of genuine scientific and professional depth is the life sciences podcast's most important ongoing challenge — and its most significant opportunity. The show that meets this standard becomes not just a media property but a genuine institution in its field — a trusted touchstone for the scientific and clinical community that looks to it for the kind of honest, rigorous engagement with the most important questions in medicine that the practitioner community both deserves and desperately needs.
